Effects of arsenic trioxide administration styles on leukocytosis

Chinese Medical Sciences Journal

Volumn 21, Issue 2, 2006, Pages 111-114

  Zhou, Jin ^a   Meng, Ran ^a,b   Sui, Xin Hua ^c   Meng, Lu ^d   Yang, Bao Feng ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c MUDANJIANG MEDICAL UNIVERSITY   (China)

^d UNIVERSITY OF GEORGIA   (United States)

Author keywords

Arsenical; Infusion regimen; Leukocytosis

Indexed keywords

ARSENIC TRIOXIDE; CD11B ANTIGEN; CD33 ANTIGEN;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; ARTICLE; CELLULAR DISTRIBUTION; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FLOW CYTOMETRY; FLUORESCENCE ANALYSIS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INFUSION RATE; LEUKEMIA CELL; LEUKOCYTOSIS; PROMYELOCYTIC LEUKEMIA; RANDOMIZED CONTROLLED TRIAL;

ANTINEOPLASTIC AGENTS; APOPTOSIS; ARSENICALS; CELL DIFFERENTIATION; CELL LINE, TUMOR; HUMANS; INFUSIONS, INTRAVENOUS; K562 CELLS; LEUKEMIA; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LEUKEMIA, MYELOID, ACUTE; LEUKEMIA, PROMYELOCYTIC, ACUTE; LEUKOCYTOSIS; OXIDES;

EID: 33745787450     PISSN: 10019294     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Binet F, Cavalli H, Moisan E, et al. Arsenic trioxide (AT) is a novel human neutrophil pro-apoptotic agent: effects of catalase on AT-induced apoptosis, degradation of cytoskeletal proteins and de novo protein synthesis. Br J Haematol 2006; 132: 349-58.
2. Woo SY, Lee MY, Jung YJ, et al. Arsenic trioxide inhibits cell growth in SH-SY5 Y and SK-N-AS neuroblastoma cell lines by a different mechanism. Pediatr Hematol Oncol 2006; 23: 231-43.
3. Carmosino I, Latagliata R, Avvisati G, et al. Arsenic trioxide in the treatment of advanced acute promyelocytic leukemia. Haematologica 2004; 89: 615-7.
4. Griffin RG, Williams BW, Park HJ, et al. Preferential action of arsenic trioxide in solid-tumor microenvironment enhances radiation therapy. Int J Radiat Oncol Biol Phys 2005; 61: 1516-22.
5. Karlsson J, ORa I, Porn-Ares I, et al. Arsenic trioxide-induced death of neuroblastoma cells involves activation of Bax and does not require p53. Clin Cancer Res 2004; 10: 3179-88.
6. Zhou J, Meng R, Wang Y, et al. Clinical Observation and following up of two administration methods of arsenic trioxide in treatment of acute promyelocytic leukemia. Chin Med J 2004; 84: 9-12.
7. Ni J, Chen G, Shen Z, et al. Pharmacokinetics of intravenous arsenic trioxide in the treatment of acute promyelocytic leukemia. Chin J Hematol 1997; 18: 250-3.
8. Paietta E. Expression of cell-surface antigens in acute promyelocytic leukaemia. Best Pract Res Clin Haematol 2003; 16: 369-85.
9. + hematopoietic precursor cells. Stem Cells 2001; 19: 492-9.
10. Daneshbod Y, Amirghofran Z, Tabei SZ. Bcl-2 expression in acute myelogenous leukemia: the relation to myeloid antigen expression and response to therapy in Iranian patients. Neoplasma 2005; 52: 109-14.
11. Klobusicka M, Kusenda J, Babusikova O. Myeloid enzymes profile related to the immunophenotypic characteristics of blast cells from patients with acute myeloid leukemia (AML) at diagnosis. Neoplasma 2005; 52: 211-8.